Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending June 29, 2021 was $752 Million (a -78.7% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss decreased by -67.25%
- Annual Consolidated Net Income/Loss for 2020 was $4.56 Billion (a -41.83% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2019 was $7.84 Billion (a 38.62% increase from previous year)
- Annual Consolidated Net Income/Loss for 2018 was $5.66 Billion (a 7.08% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending June 29, 2021 was $6.6 Billion (a 29.63% increase compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss decreased by -10.19% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 29 Jun '21 | 30 Mar '21 | 30 Dec '20 | 29 Sep '20 |
|---|---|---|---|
| $6.6 Billion | $5.09 Billion | $4.57 Billion | $7.35 Billion |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of AbbVie Inc.
Most recent Consolidated Net Income/Lossof ABBV including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of AbbVie Inc.
AbbVie Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $752.0 | $3,531.0 | – | – | – |
| 2020 | $22.0 | $2,296.0 | $-757.0 | $3,010.0 | $4,562.0 |
| 2019 | $2,801.0 | $1,884.0 | $741.0 | $2,456.0 | $7,842.0 |
| 2018 | $-1,826.0 | $2,747.0 | $1,983.0 | $2,783.0 | $5,657.0 |
| 2017 | $52.0 | $1,631.0 | $1,915.0 | $1,711.0 | $5,283.0 |
| 2016 | $1,391.0 | $1,598.0 | $1,610.0 | $1,354.0 | $5,923.0 |
| 2015 | $1,517.0 | $1,239.0 | $1,366.0 | $1,022.0 | $5,144.0 |
| 2014 | $-810.0 | $506.0 | $1,098.0 | $980.0 | $1,774.0 |
| 2013 | $1,128.0 | $964.0 | $1,068.0 | $968.0 | $4,128.0 |
| 2012 | $1,540.0 | $1,585.0 | $1,267.0 | $883.0 | $5,275.0 |
| 2011 | $1,157.0 | $13.0 | $1,540.0 | $723.2 | $3,433.0 |
| 2010 | – | – | – | – | $4,178.0 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.